CAR-T therapies

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

News

Kyverna researcher holds multi-petri dish

Kyverna builds case for CAR-T in stiff person syndrome

Kyverna has data with miv-cel in stiff person syndrome that shows durable efficacy and safety and seems to sidestep issues flagged with other CAR-Ts.

News

Legend Biotech names ex-Novartis exec as CEO

Cell therapy developer Legend Biotech has named Ingrid Zhang as its new chief executive, ending its search for new leadership.

News

BMS eyes role for new CAR-T in post-BCMA multiple myeloma

BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.

In vivo CAR-T can solve the delivery problem – but solid tum...

Unlocking the scalability of allogeneic CAR-T

Australia, CAR-T therapy, and solid tumours

Kyverna builds case for CAR-T in stiff person syndrome

Legend Biotech names ex-Novartis exec as CEO

BMS eyes role for new CAR-T in post-BCMA multiple myeloma

HHS doubles down on controversial peptides plan

Discover a new era of healthcare panel engagement: Grounded ...

CAR-T therapies

Editor's Picks